Current Projects

Sleep and Pain in Childhood Arthritis: A crossover randomized control trial comparing adequate and restricted sleep duration, and its impact on pain in adolescents with arthritis

Funder: Canadian Institutes of Health Research (CIHR)
Year Started: 2018
Role: Principal Investigator
Contact Person: Hayyah Clairman
Study Summary: Childhood arthritis is an important cause of pain for affected children and youth (adolescents). Many youth with arthritis also have trouble sleeping. They often struggle to sleep through the night, wake up earlier, and are sleepier during the day compared to healthy children. Our research group, among others, has shown a strong link between sleep and pain. The main purpose of this study is to assess the impact of changing sleeping patterns on pain, and disease activity, in teenagers with arthritis. We think that better sleep will directly lead to better health.

Patient and Caregiver Engagement in Research (PACER): Approaching for research on date of rheumatic diagnosis – a pilot project

Funder: Childhood Arthritis & Rheumatology Research Alliance (CARRA)
Year Started: 2018
Role: Co-Principal Investigator
Contact Person: Ingrid Goh
Study Summary: This project seeks to look at ways that researchers can better engage patients and caregivers in participating in research.  From development of research projects, joining research as participants, to dissemination of research results; patients and caregivers provide a unique perspective that should be incorporated when developing and operationalizing research.

The effects of exercise, creatine, and coenzyme Q10 supplementation on muscle function in children with myositis

Funder: Cure JM Foundation
Year Started: 2018
Role: Principal Investigator
Contact Person: Hayyah Clairman
Study Summary: Children with JDM are weak and get tired because their muscles aren’t able to work like healthy muscles. This can make it hard for them to do normal everyday things and can make them less happy about their lives compared to children without the disease. There are two nutritional supplements that help muscles use energy and recover after exercise: creatine and coenzyme Q10. If the muscle has more energy, it may not be as weak and may not feel as tired or sore after exercise. Because of this we want to see if having children with JDM take creatine and coenzyme Q10 can make them stronger and less tired. If this works, we hope it will let them be able to do the things that healthy children can do, and make them feel better about their lives.

Exploring Canadians’ Preferences for Healthcare Funding

Funder: N/A
Year Started: 2014
Role: Principal Investigator
Contact Person: Saunya Dover
Study Summary: The distribution of health-care funds has always been a questionable act due to subjective interpretations of society’s preferences. How are decisions made regarding the distribution of health-care funds – should more effective and more expensive treatments or less effective and significantly cheaper treatments receive funding? Should treatments targeting children or adults receive more funding? This study aims to determine what Canadians value in terms of health-care funding allocation using a discrete choice experiment approach.

Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry (including STOP–JIA, FROST, JIA, JDM, SLE registries and trials)

Funder: Childhood Arthritis & Rheumatology Research Alliance (CARRA)
Year Started: 2016
Role: Site Investigator
Contact Person: Ingrid Goh
Study Summary: The CARRA registry is an observational registry that collects clinical and patient reported information about patients with pediatric-onset rheumatic diseases. The goal of the CARRA Registry is to understand the long-term outcomes, as well as the long- and short-term safety and effectiveness of the medications used to treat pediatric rheumatic diseases. It provides opportunities for research through identification of subjects eligible for future studies and by serving as a data repository. More information can be found on the study website.

Childhood Arthritis Network-Database for Improved Outcomes (CAN-DIO)

Year Started: 2017
Role: Principal Investigator
Contact Person: Ingrid Goh
Study Summary: The purpose of this study/registry is to improve the outcomes of patients with Juvenile Idiopathic Arthritis (JIA) by collecting data from patients to form the basis for future studies involving JIA patients. Data collected from patients will include: important patient factors, therapies, serious adverse events (SAEs), and protocol-defined events of special interest. The data collected will help guide therapeutic decisions made by affected children, families and providers, serving as a model for successful collaboration between research community networks, industry, and public agencies to promote the effective and efficient evaluation of currently used therapies.

Interferon Scores in Juvenile Dermatomyositis and Correlation with Disease Activity

Year Started: 2021
Role: Co-Principal Investigator
Contact Person: Jayne MacMahon
Study Summary: Juvenile Dermatomyositis (JDM) is a potentially damaging autoimmune disease. Even with treatment, 60% of patients will have ongoing disease activity. Predicting which patients are at risk is challenging. A marker, called ‘interferon’ has been found in the blood of patients with JDM. A scoring system based on this marker has been developed. We have evidence that this score is linked to disease activity. We plan to look for the interferon score in blood samples from patients with JDM, already collected as part of other studies. We will compare the results to disease activity at the time of sampling. We plan to prove that this interferon score and disease activity are linked and that this score could be used clinically to predict outcomes.

Predicting Eye Disease in Childhood Arthritis – Uveitis Study (PEDIA-U)

Year Started: 2022
Role: Site Investigator
Contact Person: Ingrid Goh
Study Summary: Children with juvenile idiopathic arthritis (JIA) may develop uveitis (inflammation of the eye). Some children who have uveitis may not know that they have it. Untreated uveitis may cause vision loss or blindness. This study wants to see if there is something in someone’s blood or DNA that can tell who has a higher chance of getting uveitis. If we can tell that someone has a higher chance of getting uveitis, their doctor can tell them to have their eyes checked for uveitis more often. This way if they get uveitis, they can get medications sooner. Treating uveitis right away may improve the outcomes of children.

The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis, OPT-JIA

Funder: Arthritis Society and CIHR
Year Started: 2022
Role: Site Investigator
Contact Person: Ingrid Goh
Study Summary: Methotrexate is a drug commonly used to treat children with Juvenile Idiopathic Arthritis (JIA). Some children may develop side effects from methotrexate; including stomach-aches, nausea or vomiting. Ondansetron is a drug used to try to stop nausea and vomiting. In this study, we will compare two ways of prescribing ondansetron in children with JIA. The OPT-JIA trial would like to see if it is better to prescribe ondansetron at the same time that a patient starts methotrexate to prevent nausea from occurring, or only after nausea and vomiting has developed. Participants will be randomly assigned to one of the two groups. They will answer questionnaires.

Telemedicine in JDM: A Survey of Patients and Caregivers

Year Started: 2022
Role: Co-Investigator
Contact Person: Ingrid Goh
Study Summary: This project will ask patients with JDM and their caregivers about their telemedicine experience.

Telemedicine and JDM: A Survey of Healthcare Providers

Year Started: 2022
Role: Co-Investigator
Contact Person: Ingrid Goh
Study Summary: This project will ask healthcare providers for patients with JDM about their telemedicine experience.

Multimedia vs. Paper Consent

Year Started: 2021
Role: Co-Principal Investigator
Contact Person: Ingrid Goh
Study Summary: This study will compare the use of a multimedia (video) consent form with paper consent form. Participants will be asked to look at both types of forms and provide their feedback in two surveys.

Optimal Withdrawal Strategy of Methotrexate in Children with Polyarticular JIA in Clinical Remission to Prevent Disease Flare

Year Started: 2020
Role: Site Investigator
Contact Person: Ingrid Goh
Study Summary: Methotrexate (MTX) is the most widely used disease-modifying anti-rheumatic drug (DMARD) in JIA. Although a lot of information exists about starting and increasing the dose of MTX, there is limited information about how to stop it when patients in remission. This study will use data previously collected in registries to see what strategy (tapering or completely stopping) works best for stopping MTX in patients with polyarticular arthritis to avoid a future flare of their condition.

Mental Health Screening in Juvenile Myositis: Pilot & Feasibility Study

Funder: CARRA
Year Started: 2020
Role: Co-Investigator
Contact Person: Kayla Baker
Study Summary: Studies in other pediatric rheumatic diseases suggest that mental health conditions, such as depression and anxiety, are common. However, this has not been well-studied in juvenile myositis (JM). The purpose of this study is to understand if routine mental health screening is feasible and acceptable to patients with JM and their parents. The study will also assess if mental health affects physical health and health behaviors as they relate to JM. We hope to better understand the mental health needs of people with JM and how to help address these needs.

Inceptions Cohort for Juvenile Systemic Sclerosis (jSSc)

Funder: Joachim Herz Stiftung
Year Started: 2017
Role: Site Investigator
Contact Person: Kayla Baker
Study Summary: Juvenile systemic sclerosis is a rare condition. Due to this, there is limited information on how it affects children and youth, and what the most common practices and treatments are. This study is being done to try to understand more about how juvenile systemic sclerosis affects children and youth when they are first diagnosed and as they grow up. This study will also assess how accurate the criteria is that is used to diagnosis children with this condition. This is an international study, and will hopefully improve the care of children and youth with this illness across the world by standardizing care and informing doctors on the best way to monitor children and youth for possible complications.

Clinician Rated Outcomes on Musculoskeletal Health in PWH; an International Consensus

Funder: International Prophylaxis Study Group (IPSG)
Year Started: 2022
Role: Principal Investigator
Contact Person: Audrey Abad
Study Summary: The Hemophilia Joint Health Score (HJHS) 2.1 is a validated physical assessment tool for patients with hemophilia in both pediatric and adult populations. It has become the instrument of choice in many research trials. However, a limitation of the tool is the amount of time required to complete the assessment within the clinical setting. In order to determine the best tool, the priority needs of Healthcare professionals administering these assessments for clinical purposes will need to be identified as Phase 1 of the process.

Selected Publications

Methodological Studies

Randomized Placebo Phase Design

  • Abrahamyan L, Beyene J, Feng J, Chon Y, Willan AR, Schmeling H, Horneff G, Keystone EC, Feldman BM. Response times follow lognormal or gamma distribution in arthritis patients. J Clin Epidemiol. 2010 Dec; 63(12):1363-9. PMID: 20430577. View in: PubMed
  • Abrahamyan L, Li CS, Beyene J, Willan AR, Feldman BM. Survival distributions impact the power of randomized placebo-phase design and parallel groups randomized clinical trials. J Clin Epidemiol. 2011 Mar; 64(3):286-92. PMID: 20926258. View in: PubMed
  • Feldman B, Wang E, Willan A, Szalai JP. The randomized placebo-phase design for clinical trials. J Clin Epidemiol. 2001 Jun; 54(6):550-7. PMID: 11377114. View in: PubMed
  • Feldman BM. Innovative strategies for trial design. J Rheumatol Suppl. 2000 Apr; 58:4-7. PMID: 10782848. View in: PubMed

Bayesian meta–analysis of n–of–1 studies

  • Huber AM, Tomlinson GA, Koren G, Feldman BM. Amitriptyline to relieve pain in juvenile idiopathic arthritis: a pilot study using Bayesian metaanalysis of multiple N-of-1 clinical trials. J Rheumatol. 2007 May; 34(5):1125-32. PMID: 17444584. View in: PubMed
  • Sung L, Tomlinson GA, Greenberg ML, Koren G, Judd P, Ota S, Feldman BM. Serial controlled N-of-1 trials of topical vitamin E as prophylaxis for chemotherapy-induced oral mucositis in paediatric patients. Eur J Cancer. 2007 May; 43(8):1269-75. PMID: 17383174. View in: PubMed
  • Sung L, Feldman BM. N-of-1 trials: innovative methods to evaluate complementary and alternative medicines in pediatric cancer. J Pediatr Hematol Oncol. 2006 Apr; 28(4):263-6. PMID: 16679928. View in: PubMed
  • Nathan PC, Tomlinson G, Dupuis LL, Greenberg ML, Ota S, Bartels U, Feldman BM. A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design. Support Care Cancer. 2006 Mar; 14(3):268-76. PMID: 16052316. View in: PubMed

Observational Study Design

  • Johnson SR, Tomlinson GA, Hawker GA, Granton JT, Feldman BM. Propensity Score Methods for Bias Reduction in Observational Studies of Treatment Effect. Rheum Dis Clin North Am. 2018 05; 44(2):203-213. PMID: 29622292. View in: PubMed
  • Tian SY, Silverman ED, Pullenayegum E, Brown PE, Beyene J, Feldman BM. Comparative Effectiveness of Mycophenolate Mofetil for the Treatment of Juvenile-Onset Proliferative Lupus Nephritis. Arthritis Care Res (Hoboken). 2017 12; 69(12):1887-1894. PMID: 28182833. View in: PubMed
  • Lim LS, Pullenayegum E, Moineddin R, Gladman DD, Silverman ED, Feldman BM. Methods for analyzing observational longitudinal prognosis studies for rheumatic diseases: a review & worked example using a clinic-based cohort of juvenile dermatomyositis patients. Pediatr Rheumatol Online J. 2017 Mar 29; 15(1):18. PMID: 28356102. View in: PubMed
  • Abrahamyan L, Willan AR, Beyene J, Mclimont M, Blanchette V, Feldman BM. Using value-of-information methods when the disease is rare and the treatment is expensive–the example of hemophilia A. J Gen Intern Med. 2014 Aug; 29 Suppl 3:S767-73. PMID: 25029970; PMCID: PMC4124117. View in: PubMed, PubMed Central
  • Lim LS, Feldman BM. The risky business of studying prognosis. J Rheumatol. 2013 Jan; 40(1):9-15. PMID: 23204219. View in: PubMed
  • Pullenayegum EM, Feldman BM. Doubly robust estimation, optimally truncated inverse-intensity weighting and increment-based methods for the analysis of irregularly observed longitudinal data. Stat Med. 2013 Mar 15; 32(6):1054-72. PMID: 23047604. View in: PubMed
  • Johnson SR, Granton JT, Tomlinson GA, Grosbein HA, Le T, Lee P, Seary ME, Hawker GA, Feldman BM. Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease. J Rheumatol. 2012 Feb; 39(2):276-85. PMID: 22247353. View in: PubMed
  • Johnson SR, Granton JT, Tomlinson GA, Grosbein HA, Hawker GA, Feldman BM. Effect of warfarin on survival in scleroderma-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH. Belief elicitation for Bayesian priors. J Rheumatol. 2011 Mar; 38(3):462-9. PMID: 21159827. View in: PubMed
  • Johnson SR, Tomlinson GA, Hawker GA, Granton JT, Grosbein HA, Feldman BM. A valid and reliable belief elicitation method for Bayesian priors. J Clin Epidemiol. 2010 Apr; 63(4):370-83. PMID: 19926253. View in: PubMed
  • Pullenayegum EM, Lam C, Manlhiot C, Feldman BM. Fitting marginal structural models: estimating covariate-treatment associations in the reweighted data set can guide model fitting. J Clin Epidemiol. 2008 Sep; 61(9):875-81. PMID: 18486447. View in: PubMed

Outcome Measures

  • Stephens S, Beyene J, Tremblay MS, Faulkner G, Pullnayegum E, Feldman BM. Strategies for Dealing with Missing Accelerometer Rheum Dis Clin North Am. 2018 May; 44(2):317-326. PMID: 29622298. View in: PubMed
  • Feldman BM. The outcomes of haemophilia and its treatment: why we need a core set. Haemophilia. 2017 07; 23(4):485-487. PMID: 28722832. View in: PubMed
  • Church PC, Greer MC, Cytter-Kuint R, Doria AS, Griffiths AM, Turner D, Walters TD, Feldman BM. Magnetic resonance enterography has good inter-rater agreement and diagnostic accuracy for detecting inflammation in pediatric Crohn disease. Pediatr Radiol. 2017 May; 47(5):565-575. PMID: 28283726. View in: PubMed
  • Avila ML, Brandão LR, Williams S, Montoya MI, Stinson J, Kiss A, Feldman BM. Development of CAPTSureTM – a new index for the assessment of pediatric postthrombotic syndrome. J Thromb Haemost. 2016 12; 14(12):2376-2385. PMID: 27709837. View in: PubMed
  • Peters S, Ota S, Bolous E, Reich E, Chait S, Feldman BM. The Responsiveness of the Modified Childhood Health Assessment Questionnaire. J Rheumatol. 2016 10; 43(10):1904-1908. PMID: 27481906. View in: PubMed
  • Stephens SL, Tremblay MS, Faulkner G, Beyene J, Nguyen TH, Koohsari S, Limenis E, Feldman BM. Validity of the Stage of Exercise Scale in Children with Rheumatologic Conditions. J Rheumatol. 2016 12; 43(12):2189-2198. PMID: 27803137. View in: PubMed
  • Avila ML, Brandão LR, Williams S, Ward LC, Montoya MI, Stinson J, Kiss A, Lara-Corrales I, Feldman BM. Pediatric post-thrombotic syndrome in children: Toward the development of a new diagnostic and evaluative measurement tool. Thromb Res. 2016 Aug; 144:184-91. PMID: 27393923. View in: PubMed
  • Stephens S, Takken T, Esliger DW, Pullenayegum E, Beyene J, Tremblay M, Schneiderman J, Biggar D, Longmuir P, McCrindle B, Abad A, Ignas D, Van Der Net J, Feldman B. Validation of Accelerometer Prediction Equations in Children with Chronic Disease. Pediatr Exerc Sci. 2016 Feb; 28(1):117-32. PMID: 26182189. View in: PubMed
  • David JA, Feldman BM. Assessing activities, participation, and quality of life in hemophilia: relevance, current limitations, and possible options. Semin Thromb Hemost. 2015 Nov; 41(8):894-900. PMID: 26485720. View in: PubMed
  • Avila ML, Stinson J, Kiss A, Brandão LR, Uleryk E, Feldman BM. A critical review of scoring options for clinical measurement tools. BMC Res Notes. 2015 Oct 28; 8:612. PMID: 26510822. View in: PubMed
  • Adunuri NR, Feldman BM. Critical appraisal of studies measuring quality of life in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2015 May; 67(6):880-4. PMID: 25384887. View in: PubMed
  • Feldman BM, Pullaneyagum E. Response to ‘Limits of agreement between raters are required for use of HJHS 2.1 in clinical studies’. Haemophilia. 2015 Jan; 21(1):e71. PMID: 25412703. View in: PubMed
  • Luca NJ, Feldman BM. Health outcomes of pediatric rheumatic diseases. Best Pract Res Clin Rheumatol. 2014 Apr; 28(2):331-50. PMID: 24974066. View in: PubMed
  • Limenis E, Grosbein HA, Feldman BM. The relationship between physical activity levels and pain in children with juvenile idiopathic arthritis. J Rheumatol. 2014 Feb; 41(2):345-51. PMID: 24334648. View in: PubMed
  • Luca NJ, Feldman BM. Disease activity measures in paediatric rheumatic diseases. Int J Rheumatol. 2013; 2013:715352. PMID: 24089617; PMCID: PMC3781994. View in: PubMed, PubMed Central
  • Doria AS, Crawley A, Babyn P, Rayner T, McLimont M, Moineddin R, Laxer R, Feldman B. BOLD MRI at 1.5 Tesla in juvenile idiopathic arthritis: preliminary experience. Clinics (Sao Paulo). 2013 May; 68(5):721-4. PMID: 23778406; PMCID: PMC3654309. View in: PubMed, PubMed Central
  • Feldman BM. Issues in the measurement of quality of life in hemophilia. Rev Bras Hematol Hemoter. 2013; 35(5):299-301. PMID: 24255605; PMCID: PMC3832302. View in: PubMed, PubMed Central
  • Luca NJ, Feldman BM. Paediatric rheumatic disease: Defining clinically inactive disease in juvenile dermatomyositis. Nat Rev Rheumatol. 2012 Nov; 8(11):638-9. PMID: 23027027. View in: PubMed
  • Feldman BM. Implementing musculoskeletal outcome assessments in clinical practice. Haemophilia. 2012 Jul; 18 Suppl 4:120-4. PMID: 22726094. View in: PubMed
  • Poonnoose P, Keshava S, Gibikote S, Feldman BM. Outcome assessment and limitations. Haemophilia. 2012 Jul; 18 Suppl 4:125-30. PMID: 22726095. View in: PubMed
  • Webb BD, Barrera M, Beyene J, Carcao M, Daneman D, Elliott I, Gong GW, Halperin IJ, Lord S, Melville H, Narayanan UG, Ota S, Solomon M, Sung L, Young NL, Zachos M, Feldman BM. Determinants of quality of life in children with chronic somatic disease: pilot data from the GapS Questionnaire. Qual Life Res. 2013 Mar; 22(2):339-49. PMID: 22461136. View in: PubMed
  • Luca N, Feldman BM. Pediatric rheumatology: Improving the assessment of children with JIA. Nat Rev Rheumatol. 2011 Jul 05; 7(8):442-4. PMID: 21727934. View in: PubMed
  • Takken T, Stephens S, Balemans A, Tremblay MS, Esliger DW, Schneiderman J, Biggar D, Longmuir P, Wright V, McCrindle B, Hendricks M, Abad A, van der Net J, Beyene J, Feldman BM. Validation of the Actiheart activity monitor for measurement of activity energy expenditure in children and adolescents with chronic disease. Eur J Clin Nutr. 2010 Dec; 64(12):1494-500. PMID: 20877392. View in: PubMed
  • Miller ML, LeBovidge J, Feldman B. Health-related quality of life in children with arthritis. Rheum Dis Clin North Am. 2002 Aug; 28(3):493-501, vi. PMID: 12380367. View in: PubMed
  • Feldman BM, Funk SM, Bergstrom BM, Zourikian N, Hilliard P, van der Net J, Engelbert R, Petrini P, van den Berg HM, Manco-Johnson MJ, Rivard GE, Abad A, Blanchette VS. Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score. Arthritis Care Res (Hoboken). 2011 Feb; 63(2):223-30. PMID: 20862683. View in: PubMed
  • Feldman BM, Funk S, Lundin B, Doria AS, Ljung R, Blanchette V. Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG). Haemophilia. 2008 Jul; 14 Suppl 3:162-9. PMID: 18510537. View in: PubMed
  • Stephens S, Singh-Grewal D, Bar-Or O, Beyene J, Cameron B, Leblanc CM, Schneider R, Schneiderman-Walker J, Selvadurai H, Silverman E, Spiegel L, Tse SM, Wright V, Feldman BM. Reliability of exercise testing and functional activity questionnaires in children with juvenile arthritis. Arthritis Rheum. 2007 Dec 15; 57(8):1446-52. PMID: 18050186. View in: PubMed
  • Sung L, Tomlinson GA, Greenberg ML, Koren G, Judd P, Ota S, Feldman BM. Validation of the oral mucositis assessment scale in pediatric cancer. Pediatr Blood Cancer. 2007 Aug; 49(2):149-53. PMID: 16628556. View in: PubMed
  • Gong GW, Barrera M, Beyene J, Bhat S, Carcao M, Lord S, Narayanan UG, Sung L, Young NL, Feldman BM. The Gap Study (GapS) interview–developing a process to determine the meaning and determinants of quality of life in children with arthritis and rheumatic disease. Clin Exp Rheumatol. 2007 May-Jun; 25(3):486-93. PMID: 17631751. View in: PubMed
  • Gong GW, Young NL, Dempster H, Porepa M, Feldman BM. The Quality of My Life questionnaire: the minimal clinically important difference for pediatric rheumatology patients. J Rheumatol. 2007 Mar; 34(3):581-7. PMID: 17183614. View in: PubMed
  • Hilliard P, Funk S, Zourikian N, Bergstrom BM, Bradley CS, McLimont M, Manco-Johnson M, Petrini P, van den Berg M, Feldman BM. Hemophilia joint health score reliability study. Haemophilia. 2006 Sep; 12(5):518-25. PMID: 16919083. View in: PubMed
  • Doria AS, Babyn PS, Feldman B. A critical appraisal of radiographic scoring systems for assessment of juvenile idiopathic arthritis. Pediatr Radiol. 2006 Aug; 36(8):759-72. PMID: 16552589. View in: PubMed
  • Brown GT, Wright FV, Lang BA, Birdi N, Oen K, Stephens D, McComas J, Feldman BM. Clinical responsiveness of self-report functional assessment measures for children with juvenile idiopathic arthritis undergoing intraarticular corticosteroid injections. Arthritis Rheum. 2005 Dec 15; 53(6):897-904. PMID: 16342103. View in: PubMed
  • Ramanan AV, Schneider R, Batthish M, Achonu C, Ota S, McLimont M, Young NL, Feldman BM. Developing a disease activity tool for systemic-onset juvenile idiopathic arthritis by international consensus using the Delphi approach. Rheumatology (Oxford). 2005 Dec; 44(12):1574-8. PMID: 16159950. View in: PubMed
  • Sung L, Hayden J, Greenberg ML, Koren G, Feldman BM, Tomlinson GA. Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study. J Clin Epidemiol. 2005 Mar; 58(3):261-8. PMID: 15718115. View in: PubMed
  • Batthish M, Schneider R, Ramanan AV, Achonu C, Young NL, Feldman BM. What does “active disease” mean? patient and parent perceptions of disease activity in the systemic arthritis form of juvenile idiopathic arthritis (SO-JIA). Rheumatology (Oxford). 2005 Jun; 44(6):796-9. PMID: 15784631. View in: PubMed
  • Lam C, Young N, Marwaha J, McLimont M, Feldman BM. Revised versions of the Childhood Health Assessment Questionnaire (CHAQ) are more sensitive and suffer less from a ceiling effect. Arthritis Rheum. 2004 Dec 15; 51(6):881-9. PMID: 15593357. View in: PubMed
  • Sung L, Young NL, Greenberg ML, McLimont M, Samanta T, Wong J, Rubenstein J, Ingber S, Doyle JJ, Feldman BM. Health-related quality of life (HRQL) scores reported from parents and their children with chronic illness differed depending on utility elicitation method. J Clin Epidemiol. 2004 Nov; 57(11):1161-6. PMID: 15567632. View in: PubMed
  • Sung L, Greenberg ML, Young NL, McLimont M, Ingber S, Rubenstein J, Wong J, Samanta T, Doyle JJ, Stain AM, Feldman BM. Validity of a modified standard gamble elicited from parents of a hospital-based cohort of children. J Clin Epidemiol. 2003 Sep; 56(9):848-55. PMID: 14505769. View in: PubMed
  • Brunner HI, Maker D, Grundland B, Young NL, Blanchette V, Stain AM, Feldman BM. Preference-based measurement of health-related quality of life (HRQL) in children with chronic musculoskeletal disorders (MSKDs). Med Decis Making. 2003 Jul-Aug; 23(4):314-22. PMID: 12926581. View in: PubMed
  • Brunner HI, Silverman ED, Bombardier C, Feldman BM. European Consensus Lupus Activity Measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 2003 Jun 15; 49(3):335-41. PMID: 12794788. View in: PubMed
  • Sung L, Greenberg ML, Doyle JJ, Young NL, Ingber S, Rubenstein J, Wong J, Samanta T, McLimont M, Feldman BM. Construct validation of the Health Utilities Index and the Child Health Questionnaire in children undergoing cancer chemotherapy. Br J Cancer. 2003 Apr 22; 88(8):1185-90. PMID: 12698182; PMCID: PMC2747569. View in: PubMed, PubMed Central
  • Dhanani S, Quenneville J, Perron M, Abdolell M, Feldman BM. Minimal difference in pain associated with change in quality of life in children with rheumatic disease. Arthritis Rheum. 2002 Oct 15; 47(5):501-5. PMID: 12382298. View in: PubMed
  • Naraine VS, Risebrough NA, Oh P, Blanchette VS, Lee S, Stain AM, Hedden D, Teitel JM, Feldman BM. Health-related quality-of-life treatments for severe haemophilia: utility measurements using the Standard Gamble technique. Haemophilia. 2002 Mar; 8(2):112-20. PMID: 11952846. View in: PubMed
  • Dempster H, Porepa M, Young N, Feldman BM. The clinical meaning of functional outcome scores in children with juvenile arthritis. Arthritis Rheum. 2001 Aug; 44(8):1768-74. PMID: 11508427. View in: PubMed
  • Huber AM, Hicks JE, Lachenbruch PA, Perez MD, Zemel LS, Rennebohm RM, Wallace CA, Lindsley CB, Passo MH, Ballinger SH, Bowyer SL, Reed AM, White PH, Katona IM, Miller FW, Rider LG, Feldman BM. Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. J Rheumatol. 2001 May; 28(5):1106-11. PMID: 11361197. View in: PubMed
  • Feldman BM, Grundland B, McCullough L, Wright V. Distinction of quality of life, health related quality of life, and health status in children referred for rheumatologic care. J Rheumatol. 2000 Jan; 27(1):226-33. PMID: 10648043. View in: PubMed
  • Feldman BM, Ayling-Campos A, Luy L, Stevens D, Silverman ED, Laxer RM. Measuring disability in juvenile dermatomyositis: validity of the childhood health assessment questionnaire. J Rheumatol. 1995 Feb; 22(2):326-31. PMID: 7738957. View in: PubMed

Other

  • Aggarwal R, Ringold S, Khanna D, Neogi T, Johnson SR, Miller A, Brunner HI, Ogawa R, Felson D, Ogdie A, Aletaha D, Feldman BM. Distinctions between diagnostic and classification criteria? Arthritis Care Res (Hoboken). 2015 Jul; 67(7):891-7. PMID: 25776731. View in: PubMed
  • Abrahamyan L, Diamond IR, Johnson SR, Feldman BM. A new toolkit for conducting clinical trials in rare disorders. J Popul Ther Clin Pharmacol. 2014; 21(1):e66-78. PMID: 24671886. View in: PubMed
  • Johnson SR, Tomlinson GA, Hawker GA, Granton JT, Feldman BM. Methods to elicit beliefs for Bayesian priors: a systematic review. J Clin Epidemiol. 2010 Apr; 63(4):355-69. PMID: 19716263. View in: PubMed
  • Ota S, Cron RQ, Schanberg LE, O’Neil K, Mellins ED, Fuhlbrigge RC, Feldman BM. Research priorities in pediatric rheumatology: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) consensus. Pediatr Rheumatol Online J. 2008 Apr 01; 6:5. PMID: 18380905; PMCID: PMC2330140. View in: PubMed, PubMed Central
  • Abrahamyan L, Johnson SR, Beyene J, Shah PS, Feldman BM. Quality of randomized clinical trials in juvenile idiopathic arthritis. Rheumatology (Oxford). 2008 May; 47(5):640-5. PMID: 18245800. View in: PubMed
  • Feldman BM. Treating children with arthritis: towards an evidence-based culture. J Rheumatol Suppl. 2005 Jan; 72:33-5. PMID: 15660463. View in: PubMed
  • Feldman BM, Giannini EH. Where’s the evidence? Putting clinical science into pediatric rheumatology. J Rheumatol. 1996 Sep; 23(9):1502-4. PMID: 8877915. View in: PubMed

Applied Studies

Juvenile Dermatomyositis (JDM)

  • Gebreamlak A, Sawicka KM, Garrett R, Goh IY, Baker KM, Feldman BM. Currently recommended skin scores correlate highly in the assessment of patients with Juvenile Dermatomyositis (JDM). Pediatr Rheumatol 21, 63 (2023). https://doi.org/10.1186/s12969-023-00844-5

  • Dover S, Stephens S, Clairman H, Abesamis A, Jazi OA, Babji S, Marcuz J, Naraidoo N, Pan J, Pullenayegum E, Rumsey D, Whitney K, Feldman BM. Feasibility of the wingate anaerobic exercise test as a clinical measure in patients with juvenile dermatomyositis. Pediatr Rheumatol 20, 21 (2022). https://doi.org/10.1186/s12969-022-00679-6

  • Cantez S, Gross GJ, MacLusky I, Feldman BM. Cardiac findings in children with juvenile Dermatomyositis at disease presentation. Pediatr Rheumatol Online J. 2017 Jul 11; 15(1):54. PMID: 28693511. View in: PubMed
  • Huber A, Feldman BM. An update on inflammatory myositis in children. Curr Opin Rheumatol. 2013 Sep; 25(5):630-5. PMID: 23912317. View in: PubMed
  • Luca NJ, Atkinson A, Hawkins C, Feldman BM. Anti-signal recognition particle-positive juvenile polymyositis successfully treated with rituximab. J Rheumatol. 2012 Jul; 39(7):1483-5. PMID: 22753802. View in: PubMed
  • Lam CG, Manlhiot C, Pullenayegum EM, Feldman BM. Efficacy of intravenous Ig therapy in juvenile dermatomyositis. Ann Rheum Dis. 2011 Dec; 70(12):2089-94. PMID: 21978999. View in: PubMed
  • Butbul Aviel Y, Stremler R, Benseler SM, Cameron B, Laxer RM, Ota S, Schneider R, Spiegel L, Stinson JN, Tse SM, Feldman BM. Sleep and fatigue and the relationship to pain, disease activity and quality of life in juvenile idiopathic arthritis and juvenile dermatomyositis. Rheumatology (Oxford). 2011 Nov; 50(11):2051-60. PMID: 21873265. View in: PubMed
  • Batthish M, Feldman BM. Juvenile dermatomyositis. Curr Rheumatol Rep. 2011 Jun; 13(3):216-24. PMID: 21312074. View in: PubMed
  • Schmeling H, Stephens S, Goia C, Manlhiot C, Schneider R, Luthra S, Stringer E, Feldman BM. Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis. Rheumatology (Oxford). 2011 May; 50(5):885-93. PMID: 21156669. View in: PubMed
  • Stringer E, Bohnsack J, Bowyer SL, Griffin TA, Huber AM, Lang B, Lindsley CB, Ota S, Pilkington C, Reed AM, Scuccimarri R, Feldman BM. Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. J Rheumatol. 2010 Sep; 37(9):1953-61. PMID: 20595275. View in: PubMed
  • Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, Pachman LM, Pilkington C, Reed AM, Rennebohm RM, Rider LG, Wallace CA, Feldman BM. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children’s Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res (Hoboken). 2010 Feb; 62(2):219-25. PMID: 20191521. View in: PubMed
  • Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum. 2008 Nov; 58(11):3585-92. PMID: 18975314. View in: PubMed
  • Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008 Jun 28; 371(9631):2201-12. PMID: 18586175. View in: PubMed
  • Manlhiot C, Liang L, Tran D, Bitnun A, Tyrrell PN, Feldman BM. Assessment of an infectious disease history preceding juvenile dermatomyositis symptom onset. Rheumatology (Oxford). 2008 Apr; 47(4):526-9. PMID: 18304939. View in: PubMed
  • Manlhiot C, Tyrrell PN, Liang L, Atkinson AR, Lau W, Feldman BM. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content. Pediatrics. 2008 Mar; 121(3):e626-30. PMID: 18299304. View in: PubMed
  • Compeyrot-Lacassagne S, Feldman BM. Inflammatory myopathies in children. Rheum Dis Clin North Am. 2007 Aug; 33(3):525-53, vii. PMID: 17936176. View in: PubMed
  • Stringer E, Feldman BM. Advances in the treatment of juvenile dermatomyositis. Curr Opin Rheumatol. 2006 Sep; 18(5):503-6. PMID: 16896290. View in: PubMed
  • Pope E, Janson A, Khambalia A, Feldman B. Childhood acquired lipodystrophy: a retrospective study. J Am Acad Dermatol. 2006 Dec; 55(6):947-50. PMID: 17097389. View in: PubMed
  • Huber A, Feldman BM. Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going? Curr Rheumatol Rep. 2005 Dec; 7(6):441-6. PMID: 16303103. View in: PubMed
  • Ramanan AV, Campbell-Webster N, Ota S, Parker S, Tran D, Tyrrell PN, Cameron B, Spiegel L, Schneider R, Laxer RM, Silverman ED, Feldman BM. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum. 2005 Nov; 52(11):3570-8. PMID: 16255046. View in: PubMed
  • Akikusa JD, Tennankore DK, Levin AV, Feldman BM. Eye findings in patients with juvenile dermatomyositis. J Rheumatol. 2005 Oct; 32(10):1986-91. PMID: 16206356 .View in: PubMed
  • Compeyrot-Lacassagne S, Feldman BM. Inflammatory myopathies in children. Pediatr Clin North Am. 2005 Apr; 52(2):493-520, vi-vii. PMID: 15820377. View in: PubMed
  • Ramanan AV, Feldman BM. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am. 2002 Nov; 28(4):833-57. PMID: 12506775. View in: PubMed
  • Ramanan AV, Feldman BM. Clinical outcomes in juvenile dermatomyositis. Curr Opin Rheumatol. 2002 Nov; 14(6):658-62. PMID: 12410087. View in: PubMed
  • Tse S, Lubelsky S, Gordon M, Al Mayouf SM, Babyn PS, Laxer RM, Silverman ED, Schneider R, Feldman BM. The arthritis of inflammatory childhood myositis syndromes. J Rheumatol. 2001 Jan; 28(1):192-7. PMID: 11196524. View in: PubMed
  • Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol. 2000 Oct; 27(10):2498-503. PMID: 11036850. View in: PubMed
  • Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P, MacNeil I, Momy JA, Avery G, Feldman BM. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum. 2000 Mar; 43(3):541-9. PMID: 10728746. View in: PubMed
  • Laxer RM, Feldman BM. General and local scleroderma in children and dermatomyositis and associated syndromes. Curr Opin Rheumatol. 1997 Sep; 9(5):458-64. PMID: 9309202. View in: PubMed
  • Feldman BM, Reichlin M, Laxer RM, Targoff IN, Stein LD, Silverman ED. Clinical significance of specific autoantibodies in juvenile dermatomyositis. J Rheumatol. 1996 Oct; 23(10):1794-7. PMID: 8895161. View in: PubMed

Haemophilia

  • Feldman BM, Rivard GE, Babyn P, Wu JKM, Steele M, Poon MC, Card RT, Israels SJ, Laferriere N, Gill K, Chan AK, Carcao M, Klaassen RJ, Cloutier S, Price VE, Dover S, Blanchette VS. Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort. Lancet Haematol. 2018 Jun; 5(6):e252-e260. PMID: 29731369. View in: PubMed
  • Carneiro JDA, Blanchette V, Ozelo MC, Antunes SV, Villaca PR, Young NL, Castro D, Brandão LR, Carcao M, Abad A, Feldman BM. Comparing the burden of illness of haemophilia between resource-constrained and unconstrained countries: the São Paulo-Toronto Hemophilia Study. Haemophilia. 2017 Sep; 23(5):682-688. PMID: 28440005. View in: PubMed
  • Crivianu-Gaita V, Rivard GE, Carcao M, Teitel J, St-Louis J, Blanchette V, Pullenayegum E, Abad A, Feldman BM. Pilot study of once-a-day prophylaxis for youth and young adults with severe haemophilia A. Haemophilia. 2016 Sep; 22(5):e401-5. PMID: 27481574. View in: PubMed
  • Hilliard P, Zourikian N, Blanchette V, Chan A, Elliott B, Israels SJ, Nilson J, Poon MC, Laferriere N, Van Neste C, Jarock C, Wu J, McLimont M, Feldman B. Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study. J Thromb Haemost. 2013 Mar; 11(3):460-6. PMID: 23301594. View in: PubMed
  • Feldman BM, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Hoots K, Mantovani L, Willan AR, Schramm W. Haemophilia prophylaxis: how can we justify the costs? Haemophilia. 2012 Sep; 18(5):680-4. PMID: 22507524. View in: PubMed
  • Hang MX, Blanchette VS, Pullenayegum E, McLimont M, Feldman BM. Age at first joint bleed and bleeding severity in boys with severe hemophilia A: Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost. 2011 May; 9(5):1067-9. PMID: 21320278. View in: PubMed
  • Risebrough N, Oh P, Blanchette V, Curtin J, Hitzler J, Feldman BM. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. Haemophilia. 2008 Jul; 14(4):743-52. PMID: 18422610. View in: PubMed
  • Nicholson A, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Hoots K, Mantovani L, Schramm W, van Hout BA, Willan AR, Feldman BM. Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group. Haemophilia. 2008 Jan; 14(1):127-32. PMID: 18005148. View in: PubMed
  • Feldman BM, Aledort L, Bullinger M, Delaney FM, Doria AS, Funk S, Giangrande P, Lundin B, Manco-Johnson M, Miners A, Scriba PC, Srivastava A, Schramm W, Blanchette VS. The economics of haemophilia prophylaxis: governmental and insurer perspectives. Proceedings of the Second International Prophylaxis Study Group (IPSG) symposium. Haemophilia. 2007 Nov; 13(6):745-9. PMID: 17850325. View in: PubMed
  • Ota S, Mclimont M, Carcao MD, Blanchette VS, Graham N, Paradis E, Feldman BM. Definitions for haemophilia prophylaxis and its outcomes: the Canadian consensus study. Haemophilia. 2007 Jan; 13(1):12-20. PMID: 17212719. View in: PubMed
  • Feldman BM, Pai M, Rivard GE, Israels S, Poon MC, Demers C, Robinson S, Luke KH, Wu JK, Gill K, Lillicrap D, Babyn P, McLimont M, Blanchette VS. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost. 2006 Jun; 4(6):1228-36. PMID: 16706965.V iew in: PubMed
  • Feldman BM, Babyn P, Doria AS, Heijnen L, Jacobson J, Kilcoyne R, Lundin B, Manco-Johnson M, McLimont M, Petrini P, Pettersson H, Blanchette VS. Proceedings of the International Haemophilia Prophylaxis Study Group Meeting, November 2003, Montreal, PQ, Canada. Haemophilia. 2005 Jan; 11(1):58-63. PMID: 15660990. View in: PubMed
  • Kern M, Blanchette V, Stain AM, Einarson TR, Feldman BM. Clinical and cost implications of target joints in Canadian boys with severe hemophilia A. J Pediatr. 2004 Nov; 145(5):628-34. PMID: 15520762. View in: PubMed
  • Revel-Vilk S, Golomb MR, Achonu C, Stain AM, Armstrong D, Barnes MA, Anderson P, Logan WJ, Sung L, McNeely M, Blanchette V, Feldman BM. Effect of intracranial bleeds on the health and quality of life of boys with hemophilia. J Pediatr. 2004 Apr; 144(4):490-5. PMID: 15069398. View in: PubMed
  • Carcao M, Ungar WJ, Feldman BM. Cost-utility analysis in evaluating prophylaxis in haemophilia. Haemophilia. 2004 Mar; 10 Suppl 1:50-7. PMID: 14987249. View in: PubMed
  • Feldman BM. Preventing joint damage from hemophilia. J Rheumatol. 2000 Jul; 27(7):1579-81. PMID: 10914833. View in: PubMed

Fitness/Exercise Studies

  • Heale LD, Dover S, Goh YI, Maksymiuk VA, Wells GD, Feldman BM. A wearable activity tracker intervention for promoting physical activity in adolescents with juvenile idiopathic arthritis: a pilot study. Pediatr Rheumatol Online J. 2018 Oct 22; 16(1):66. PMID: 30348203. View in: PubMed
  • Feldman BM. Exercise as Medicine for Children with Arthritis. J Rheumatol. 2017 08; 44(8):1103-1105. PMID: 28765342. View in: PubMed
  • Hutzal CE, Wright FV, Stephens S, Schneiderman-Walker J, Feldman BM. A qualitative study of fitness instructors’ experiences leading an exercise program for children with juvenile idiopathic arthritis. Phys Occup Ther Pediatr. 2009; 29(4):409-25. PMID: 19916825.View in: PubMed
  • Stephens S, Feldman BM, Bradley N, Schneiderman J, Wright V, Singh-Grewal D, Lefebvre A, Benseler SM, Cameron B, Laxer R, O’Brien C, Schneider R, Silverman E, Spiegel L, Stinson J, Tyrrell PN, Whitney K, Tse SM. Feasibility and effectiveness of an aerobic exercise program in children with fibromyalgia: results of a randomized controlled pilot trial. Arthritis Rheum. 2008 Oct 15; 59(10):1399-406. PMID: 18821656.View in: PubMed
  • Singh-Grewal D, Schneiderman-Walker J, Wright V, Bar-Or O, Beyene J, Selvadurai H, Cameron B, Laxer RM, Schneider R, Silverman ED, Spiegel L, Tse S, Leblanc C, Wong J, Stephens S, Feldman BM. The effects of vigorous exercise training on physical function in children with arthritis: a randomized, controlled, single-blinded trial. Arthritis Rheum. 2007 Oct 15; 57(7):1202-10. PMID: 17907238.View in: PubMed
  • Singh-Grewal D, Wright V, Bar-Or O, Feldman BM. Pilot study of fitness training and exercise testing in polyarticular childhood arthritis. Arthritis Rheum. 2006 Jun 15; 55(3):364-72. PMID: 16739204.View in: PubMed

Juvenile Idiopathic Arthritis (JIA)

  • Verstegen RHJ , Shrader P, Balevic SJ, Beukelman T, Correll C, Dennos A, Phillips T, Feldman BM. Dosing Variation at Initiation of Adalimumab and Etanercept and Clinical Outcomes in Juvenile Idiopathic Arthritis: A Childhood Arthritis and Rheumatology Research Alliance Registry Study. Arthritis Care & Research. 2023 Feb;75(2):410-422. PMID: 35040593.
  • Lee JJY, Eng SWM, Guzman J, Duffy CM, Tucker LB, Oen K, Yeung RSM, Feldman BM, ReACCh-Out Investigators. A Comparison of International League of Associations for Rheumatology and Pediatric Rheumatology International Trials Organization Classification Systems for Juvenile Idiopathic Arthritis Among Children in a Canadian Arthritis Cohort. Arthritis Rheumatol. 2022 Aug;74(8) 1409-1419. PMID: 35289119.
  • Lee JJY, Eng SWM, Guzman J, Duffy CM, Tucker LB, Oen K, Yeung RSM, Feldman BM. A Comparison of International League of Associations for Rheumatology and Pediatric Rheumatology International Trials Organization Classification Systems for Juvenile Idiopathic Arthritis Among Children in a Canadian Arthritis Cohort. Arthritis Rheumatol, 2022 Mar;74: 1409-1419. https://doi.org/10.1002/art.42113
  • Stinson JN, Toomey PC, Stevens BJ, Kagan S, Duffy CM, Huber A, Malleson P, McGrath PJ, Yeung RS, Feldman BM. Asking the experts: exploring the self-management needs of adolescents with arthritis. Arthritis Rheum. 2008 Jan 15; 59(1):65-72. PMID: 18163408. View in: PubMed
  • Singh-Grewal D, Schneider R, Bayer N, Feldman BM. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum. 2006 May; 54(5):1595-601. PMID: 16645998. View in: PubMed
  • Spiegel LR, Schneider R, Lang BA, Birdi N, Silverman ED, Laxer RM, Stephens D, Feldman BM. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum. 2000 Nov; 43(11):2402-9. PMID: 11083261. View in: PubMed
  • Feldman BM, Birdi N, Boone JE, Dent PB, Duffy CM, Ellsworth JE, Lang BA, Laxer RM, Lewkonia RM, Malleson PN, Oen KG, Paquin JD, Rosenberg AM, Schneider R, Silverman ED. Seasonal onset of systemic-onset juvenile rheumatoid arthritis. J Pediatr. 1996 Oct; 129(4):513-8. PMID: 8859257. View in: PubMed
  • Feldman BM, Silverman ED. Methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr. 1991 Jun; 118(6):992-3. PMID: 2040940. View in: PubMed

Other

  • Nulman I, Koren G, Rovet J, Barrera M, Streiner DL, Feldman BM. Neurodevelopment of children prenatally exposed to selective reuptake inhibitor antidepressants: Toronto sibling study. J Clin Psychiatry. 2015 Jul; 76(7):e842-7. PMID: 26231010. View in: PubMed
  • Nulman I, Koren G, Rovet J, Barrera M, Pulver A, Streiner D, Feldman B. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am J Psychiatry. 2012 Nov; 169(11):1165-74. PMID: 23128923. View in: PubMed
  • Lang BA, Yeung RS, Oen KG, Malleson PN, Huber AM, Riley M, Ebbeson R, Ramsey SE, Laxer RM, Silverman ED, McCrindle BW, Ratnapalan S, Feldman BM. Corticosteroid treatment of refractory Kawasaki disease. J Rheumatol. 2006 Apr; 33(4):803-9. PMID: 16583481. View in: PubMed
  • Scolnik D, Matthews P, Caulfeild J, Williams C, Feldman BM. Pagers in a busy paediatric emergency waiting room: A randomized controlled trial. Paediatr Child Health. 2003 Sep; 8(7):422-6. PMID: 20019948; PMCID: PMC2791651. View in: PubMed, PubMed Central
  • Hagen LE, Schneider R, Stephens D, Modrusan D, Feldman BM. Use of complementary and alternative medicine by pediatric rheumatology patients. Arthritis Rheum. 2003 Feb 15; 49(1):3-6. PMID: 12579587. View in: PubMed
  • Sung L, Greenberg ML, Koren G, Tomlinson GA, Tong A, Malkin D, Feldman BM. Vitamin E: the evidence for multiple roles in cancer. Nutr Cancer. 2003; 46(1):1-14. PMID: 12925298.View in: PubMed
  • Brunner HI, Chan WS, Ginsberg JS, Feldman BM. Longterm anticoagulation is preferable for patients with antiphospholipid antibody syndrome. result of a decision analysis. J Rheumatol. 2002 Mar; 29(3):490-501. PMID: 11908562. View in: PubMed
  • Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM. Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum. 2002 Feb; 46(2):436-44. PMID: 11840446. View in: PubMed
  • Uziel Y, Laxer RM, Krafchik BR, Yeung RS, Feldman BM. Children with morphea have normal self-perception. J Pediatr. 2000 Nov; 137(5):727-30. PMID: 11060543. View in: PubMed
  • Feldman BM, Stephens D, Wang EE. How should excess admission laboratory test utilization be curtailed? –paediatricians’ preferences. Clin Invest Med. 1995 Dec; 18(6):502-9. PMID: 8714793. View in: PubMed
  • Feldman BM, Zabriskie JB, Silverman ED, Laxer RM. Diagnostic use of B-cell alloantigen D8/17 in rheumatic chorea. J Pediatr. 1993 Jul; 123(1):84-6. PMID: 8320631. View in: PubMed

Find the complete list of published work on Dr. Feldman’s Google Scholar profile.

Funding Sources

Melanie Pozez_Final
S_QmpO9w
pcori
cihr-logo
xJdDhFDU_400x400
images
5-11_nce
Arthritis Foundation logo (PRNewsFoto/Arthritis Foundation)
carra